6/13/2013

Immune Design will work with the Ludwig Institute for Cancer Research and the Cancer Research Institute to test a vaccine and adjuvant in ongoing clinical trials for other cancer immunotherapies. The Column Group, Versant Ventures and Alta Partners have invested $50 million in Immune Design, and the CEO expects to launch a new funding round soon.

Full Story:
Xconomy

Related Summaries